文献速递鼻科

鼻息肉治疗中度普利尤单抗的不良事件:FDA不良事件报告系统分析

Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System.
PubMed 文献 · Laryngoscope · 2021-12-16

本研究基于FAERS数据库回顾性分析2019Q1至2021Q2期间度普利尤单抗相关不良事件,其中慢性鼻窦炎伴鼻息肉(CRSwNP)治疗相关报告911例,13.3%为严重反应,3例死亡。CRSwNP组个体不良事件数量为2.99,低于哮喘组的3.44和特应性皮炎组的3.18(P < .001)。作者认为CRSwNP治疗相关个体不良事件较少,女性及年长者较多,但男性严重不良事件倾向更高。

要点

  • CRSwNP治疗相关度普利尤单抗不良事件报告911例,其中121例(13.3%)为严重反应,3例死亡。
  • CRSwNP组个体不良事件数量2.99,低于哮喘组3.44和特应性皮炎组3.18(P < .001)。
  • CRSwNP组男性个体不良事件报告风险比为0.84,年长者(>50岁)为1.12;严重不良事件报告比值比男性1.37、年长者1.39,均未达统计学显著。

核心结论

  • 尽管FAERS存在局限性,本分析提示CRSwNP治疗与其他适应症相比与更少的个体不良事件相关。
  • 女性和年长者经历更多个体不良事件,但男性倾向于有更严重的度普利尤单抗相关不良事件。

研究设计与样本

  • 回顾性数据库研究,查询FAERS中2019Q1至2021Q2的度普利尤单抗相关不良事件报告。
  • 共纳入15411条度普利尤单抗相关不良事件观察记录,其中911条为CRSwNP治疗相关。
  • 采用零截断泊松回归预测个体不良事件数量,逻辑回归预测严重不良事件。

主要发现

  • CRSwNP治疗相关911例报告中,121例(13.3%)为严重反应,3例死亡。
  • CRSwNP治疗相关常见个体不良事件为皮肤科症状(13.9%)、全身性症状(13.3%)和注射部位症状(10.8%)。
  • CRSwNP治疗相关个体不良事件数量为2.99 [2.81, 3.17],哮喘组为3.44 [3.32, 3.56],特应性皮炎组为3.18 [3.13, 3.24](Kruskal-Wallis检验,P < .001)。
  • CRSwNP治疗组中,男性个体不良事件报告风险比为0.84 [0.77, 0.92],年长者(>50岁)为1.12 [1.04, 1.22]。
  • CRSwNP治疗组中,男性严重不良事件报告比值比为1.37 [0.91, 2.04],年长者(>50岁)为1.39 [0.93, 2.08]。

局限性

  • 原文指出FAERS存在局限性,但未具体说明局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Dupilumab was the first biologic approved to treat chronic rhinosinusitis with nasal polyps (CRSwNP). While the risk of adverse events in phase-III clinical trials was low, dupilumab-associated adverse reactions (DAR) with real-world use is unknown and potentially under-reported. We aimed to evaluate DAR for CRSwNP treatment (CRSwNP-tx) using the FDA Adverse Event Reporting System (FAERS). STUDY DESIGN: Retrospective database study. METHODS: FAERS was queried for DAR from 2019Q1 to 2021Q2. Individual DAR (iDAR) were categorized and quantitatively compared between treatment groups (CRSwNP, asthma, atopic dermatitis). Zero-truncated Poisson regression was modeled to predict the number of iDAR, and logistic regression was modeled to predict serious DARs. RESULTS: There were 15,411 DAR observations; 911 for CRSwNP-tx, of which 121 (13.3%) had serious reactions and 3 died. Common CRSwNP-tx iDAR were dermatologic (13.9%), generalized (13.3%), and injection-site (10.8%) symptoms. The number of CRSwNP-tx iDAR was 2.99 [2.81, 3.17], compared to 3.44 [3.32, 3.56] for asthma and 3.18 [3.13, 3.24] for atopic dermatitis (Kruskal-Wallis test, P < .001). For CRSwNP-tx, iDAR reported-risk-ratio was 0.84 [0.77, 0.92] among men and 1.12 [1.04, 1.22] among older adults (>50). Serious DAR reported-odds-ratio was 1.37 [0.91, 2.04] among men and 1.39 [0.93, 2.08] among older adults. CONCLUSIONS: While there are limitations with FAERS, this analysis suggests CRSwNP-tx is associated with fewer iDAR compared with other treatment indications. More iDAR are experienced among women and older adults, but men tend to have more serious DAR. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:2307-2313, 2022.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Swisher AR, Kshirsagar RS, Adappa ND, et al. Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System. Laryngoscope. 2021. PMID: 34918342. doi:10.1002/lary.29992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。